Drug Profile
Cevostamab - Genentech
Alternative Names: BFCR-4350A; RG 6160; RO-7187797Latest Information Update: 30 Jan 2024
Price :
$50
*
At a glance
- Originator Genentech
- Developer Genentech; Roche
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Multiple myeloma
Most Recent Events
- 09 Dec 2023 Pharmacodynamics data from a phase I trial in multiple myeloma presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 25 Jul 2023 Genentech initiates enrolment in a phase I trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Australia and South Korea (IV, Infusion) (NCT05927571) (EudraCT2022-501724-15-00)
- 03 Jul 2023 Genentech plans a phase I trial for Multiple Myeloma (Combination therapy, Second-line therapy or greater) (IV), in July 2023 (NCT05927571) (EudraCT2022-501724-15-00)